Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET
Company Participants
Joshua Higa - Vice President of Investor Relations
Emil Kakkis - Chief Executive Officer & President
Erik Harris - Chief Commercial Officer
Howard Horn - Chief Financial Officer
Eric Crombez - Chief Medical Officer
Conference Call Participants
Anupam Rama - JPMorgan
Dae Gon Ha - Stifel
Michael Riad - Morgan Stanley
Tazeen Ahmad - Bank of America
Kristen Kluska - Cantor Fitzgerald
Maury Raycroft - Jefferies
Yaron Werber - TD Cowen
Laura Chico - Wedbush.
Operator
Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call.
It is now my pleasure to turn the call over to Joshua Higa, Vice President of Investor Relations.
Joshua Higa
Thank you. We've issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; Eric Crombez, Chief Medical Officer; Aaron Olsen, Senior Vice President of Corporate Strategy and Finance; and Ted Rozinka, Chief Accounting Officer.
I'd like to remind everyone that during today's call we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
Emil Kakkis
Thanks, Josh, and good afternoon, everyone. Before we get started, I'd like to welcome our new CFO, Howard Horn to the call. To say, he has hit the ground running is an understatement. He already has an Ultragenyx Analyst Day and a financing under his belt. We're happy to have him on board as we prepare for our Catalyst Rich 2024.
It's great to see many of you at our Analyst Day a few weeks ago. We hope that the new data shared along with the positive clinical impressions of the investigators on two of our programs showed you why we have confidence in our lead therapeutic candidates and their potential to transform debilitating diseases with limited or no treatment options.
We kicked off the day by sharing new data from the Orbit study for setrusumab in osteogenesis imperfecta, and has been prevented a few days earlier at ASBMR the America Society for Bone Mineral Research 2023 Annual Meeting. Interim data from the Phase 2 portion of the study demonstrated that setrusumab significantly reduced the analyzed fracture rate by 67% after at least six months of treatment and continue to demonstrate ongoing substantial increases in lumbar spine bone mineral density reaching 19% in just six months in the younger patients.